Neurocrine Biosciences traded at $120.21 this Tuesday December 6th, decreasing $3.79 or 3.06 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences lost 0.69 percent. Over the last 12 months, its price rose by 46.15 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 122.70 by the end of this quarter and at 111.16 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
120.21
Daily Change
-3.06%
Yearly
46.15%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 163.72 -0.22 -0.13% 34.74%
Acadia Pharmaceuticals 14.90 -0.34 -2.23% -30.11%
Acorda Therapeutics 0.57 -0.01 -2.53% -78.86%
Agios Pharmaceuticals 28.60 -1.20 -4.03% -12.51%
ALKERMES 24.84 -0.67 -2.63% 10.74%
Alnylam Pharmaceuticals 219.64 -6.56 -2.90% 21.83%
Amgen 283.29 -1.62 -0.57% 34.06%
Aptinyx Inc 0.25 -0.01 -2.00% -89.25%
Biogen 291.47 -1.28 -0.44% 28.50%
BioMarin Pharmaceutical 102.22 -1.31 -1.27% 18.69%
Cytokinetics 37.00 -1.12 -2.94% -1.25%
Dynavax Technologies 11.61 -0.69 -5.61% -19.65%
Enanta Pharmaceuticals 42.37 -0.69 -1.60% -45.44%
Exelixis 16.67 -0.55 -3.19% 0.60%
Gilead Sciences 87.96 -0.02 -0.02% 26.29%
Halozyme Therapeutics 56.38 0.44 0.79% 74.28%
Intercept Pharmaceuticals 13.99 -0.33 -2.30% -17.46%
Incyte Corp 82.54 -1.54 -1.83% 23.69%
Ionis Pharmaceuticals 38.03 -0.95 -2.44% 24.40%
Intra Cellular Therapies 53.22 -1.03 -1.90% 41.13%
Neurocrine Biosciences 120.21 -3.79 -3.06% 46.15%
Nektar Therapeutics 2.91 -0.06 -2.02% -76.11%
Pfizer 49.71 -1.02 -2.01% -3.89%
Prothena 58.58 -1.81 -3.00% 18.68%
Ultragenyx Pharmaceutical 39.08 -0.76 -1.90% -53.72%
Regeneron Pharmaceuticals 745.99 -9.91 -1.31% 17.46%
Repligen 168.05 -10.56 -5.91% -35.03%
Rigel Pharmaceuticals 0.92 -0.03 -3.15% -64.88%
Sarepta Therapeutics 120.30 -2.67 -2.17% 40.98%
Teva Pharmaceutical Industries Ltd 2,947.00 -38.00 -1.27% 12.27%
Vertex Pharmaceuticals 311.81 -5.79 -1.82% 51.94%
Xoma 19.49 -0.03 -0.15% -12.25%

Indexes Price Day Year
USND 11015 -225.05 -2.00% -29.78%
US2000 1813 -27.65 -1.50% -19.58%

Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.